{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:39:07Z","timestamp":1790217547707,"version":"4.1.0"},"reference-count":244,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejpb.2025.114915","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T23:18:00Z","timestamp":1762730280000},"page":"114915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Review of design strategies for active targeted drug delivery systems for pancreatic cancer"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2912-6085","authenticated-orcid":false,"given":"Aysha","family":"Rahmatulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7475-8231","authenticated-orcid":false,"given":"Yuzhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114915_b0005","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA: A Cancer J. Clin. 70 (2020) 7\u201330. Doi:10.3322\/caac.21590.","DOI":"10.3322\/caac.21590"},{"key":"10.1016\/j.ejpb.2025.114915_b0010","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early detection of pancreatic cancer: opportunities and challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2025.114915_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073995","article-title":"Advances in the management of pancreatic cancer","author":"Del Chiaro","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ejpb.2025.114915_b0020","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2025.114915_b0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/OP.22.00328","article-title":"Pancreatic adenocarcinoma management","volume":"19","author":"Jiang","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ejpb.2025.114915_b0030","unstructured":"Cancer Society: Cancer Facts and Figures 2024, (2024)."},{"key":"10.1016\/j.ejpb.2025.114915_b0035","doi-asserted-by":"crossref","unstructured":"N. Health Commission of the People's Republic of China, National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version), Chin. J. Cancer Res. 34 (2022) 238\u2013255. doi: 10.21147\/j.issn.1000-9604.2022.03.05.","DOI":"10.21147\/j.issn.1000-9604.2022.03.05"},{"key":"10.1016\/j.ejpb.2025.114915_b0040","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2025.114915_b0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.semcancer.2021.05.030","article-title":"Curing pancreatic cancer","volume":"76","author":"Traub","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejpb.2025.114915_b0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2025.114915_b0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-024-01613-x","article-title":"Consensus, debate, and prospective on pancreatic cancer treatments","volume":"17","author":"Wang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0060","first-page":"177","article-title":"Choice of drug therapy for pancreatic cancer","volume":"16","author":"Yang","year":"2023","journal-title":"Chin. J. Clin. Rational Drug Use"},{"key":"10.1016\/j.ejpb.2025.114915_b0065","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","author":"Attia","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114915_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216979","article-title":"The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks","volume":"594","author":"Luo","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125000","article-title":"Reverse engineering of Onivyde\u00ae - Irinotecan liposome injection","volume":"669","author":"Gan","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114915_b0080","unstructured":"C. for D.E. and Research, U.S. Food and Drug Administration. (2024, February 13). FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma, FDA (2024). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma (accessed January 15, 2025)."},{"key":"10.1016\/j.ejpb.2025.114915_b0085","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s40265-020-01336-6","article-title":"Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2025.114915_b0090","doi-asserted-by":"crossref","first-page":"S930","DOI":"10.1016\/j.annonc.2024.08.1585","article-title":"1522P S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil\/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)","volume":"35","author":"Tozuka","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0095","article-title":"Nano-drug delivery system for pancreatic cancer: a visualization and bibliometric analysis","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114915_b0100","first-page":"97","article-title":"Targeted drug delivery in pancreatic cancer","volume":"2010","author":"Yu","year":"1805","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-020-00184-0","article-title":"Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma","volume":"9","author":"Gao","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0110","doi-asserted-by":"crossref","unstructured":"Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians 70 (2020) 313\u2013313. 10.3322\/caac.21609.","DOI":"10.3322\/caac.21609"},{"key":"10.1016\/j.ejpb.2025.114915_b0115","doi-asserted-by":"crossref","unstructured":"Advancing on pancreatic cancer, Nat. Rev. Gastroenterol. Hepatol. 18 (2021) 447\u2013447. doi: 10.1038\/s41575-021-00479-5.","DOI":"10.1038\/s41575-021-00479-5"},{"key":"10.1016\/j.ejpb.2025.114915_b0120","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2025.114915_b0125","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","article-title":"International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis","volume":"28","author":"Ilic","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2025.114915_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","article-title":"Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis","volume":"520","author":"Cai","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b0135","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2019.14699","article-title":"Pancreatic cancer","volume":"322","author":"Moore","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2025.114915_b0140","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/cac2.12204","article-title":"Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review","volume":"41","author":"Yang","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ejpb.2025.114915_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-024-06930-0","article-title":"Emerging mechanisms and promising approaches in pancreatic cancer metabolism","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejpb.2025.114915_b0150","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.7150\/thno.64805","article-title":"Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2025.114915_b0155","article-title":"Targeting Trop-2 in cancer: recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Rev. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0160","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.78.8.5147","article-title":"Human trophoblast cell-surface antigens defined by monoclonal antibodies","volume":"78","author":"Lipinski","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejpb.2025.114915_b0165","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","volume":"99","author":"Fong","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0175","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of mesothelin in pancreatic ductal adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ejpb.2025.114915_b0180","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/ijms21114067","article-title":"From malignant progression to therapeutic targeting: current insights of mesothelin in pancreatic ductal adenocarcinoma","volume":"21","author":"Montemagno","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.ejpb.2025.114915_b0185","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1158\/0008-5472.CAN-07-0474","article-title":"High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor\u2013dependent MCAT Motif","volume":"67","author":"Hucl","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1541-7786.MCR-19-0688","article-title":"Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases","volume":"18","author":"Avula","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7150\/jca.88261","article-title":"Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy","volume":"15","author":"Tong","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0200","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/oncsis.2013.16","article-title":"MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes","volume":"2","author":"Nath","year":"2013","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejpb.2025.114915_b0205","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1039\/C9NR04976B","article-title":"Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer","volume":"12","author":"Zou","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2025.114915_b0210","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41388-022-02587-1","article-title":"Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis","volume":"42","author":"Bhatia","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ejpb.2025.114915_b0215","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1038\/s41388-022-02493-6","article-title":"Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma","volume":"41","author":"Lakshmanan","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejpb.2025.114915_b0220","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cncr.27734","article-title":"Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy","volume":"119","author":"Bauer","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12029-017-0007-x","article-title":"Predictive value of serum carbohydrate antigen 19-9 (CA19-9) for early mortality in advanced pancreatic cancer","volume":"49","author":"Us\u00f3n Junior","year":"2018","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0230","doi-asserted-by":"crossref","unstructured":"R. Nedaeinia, A. Avan, M. Manian, R. Salehi, M. Ghayour-Mobarhan, EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies, Curr. Drug Targ. 15 (n.d.) 1293\u20131301. doi: 10.2174\/1389450115666141125123003.","DOI":"10.2174\/1389450115666141125123003"},{"key":"10.1016\/j.ejpb.2025.114915_b0235","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.2147\/IJN.S226628","article-title":"Epidermal growth factor receptor and its role in pancreatic cancer treatment mediated by nanoparticles","volume":"14","author":"Grapa","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2025.114915_b0240","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.ejca.2004.01.036","article-title":"Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas","volume":"40","author":"Ryschich","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.756895","article-title":"Role of TFRC as a novel prognostic biomarker and in immunotherapy for pancreatic carcinoma","volume":"9","author":"Yang","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejpb.2025.114915_b0250","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/ph17111556","article-title":"Integrin Targeting and beyond: enhancing cancer treatment with dual-targeting RGD (arginine\u2013glycine\u2013aspartate) strategies","volume":"17","author":"Bogdanovi\u0107","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejpb.2025.114915_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.ejpb.2025.114915_b0260","doi-asserted-by":"crossref","unstructured":"Y. Jie, W. Peng, Y.-Y. Li, Identification of novel candidate biomarkers for pancreatic adenocarcinoma based on TCGA cohort, Aging-US 13 (2021) 5698\u20135717. doi: 10.18632\/aging.202494.","DOI":"10.18632\/aging.202494"},{"key":"10.1016\/j.ejpb.2025.114915_b0265","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s12010-012-9752-2","article-title":"Detection and clinical significance of CD44v6 and integrin-\u03b21 in pancreatic cancer patients using a triplex real-time RT-PCR assay","volume":"167","author":"Zhou","year":"2012","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0270","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13046-021-01946-2","article-title":"Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression","volume":"40","author":"Kemper","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0275","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.3390\/cancers14143377","article-title":"Integrin?1 in pancreatic cancer: expressions, functions, and clinical implications","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2025.114915_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111960","article-title":"HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration","volume":"390","author":"Sliker","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0285","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1111\/bph.15028","article-title":"GPCRs in pancreatic adenocarcinoma: contributors to tumour biology and novel therapeutic targets","volume":"177","author":"Sriram","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114915_b0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/biomedicines6020065","article-title":"Utilizing peptide ligand GPCRs to image and treat pancreatic cancer","volume":"6","author":"Matters","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejpb.2025.114915_b0295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12943-017-0627-6","article-title":"Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-\u03baB signaling pathway","volume":"16","author":"Wang","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170390","article-title":"The G protein-coupled receptor RAI3 is an independent prognostic factor for pancreatic cancer survival and regulates proliferation via STAT3 phosphorylation","volume":"12","author":"Jahny","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2025.114915_b0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000434","article-title":"GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors","volume":"17","author":"Sriram","year":"2019","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejpb.2025.114915_b0310","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s13046-023-02850-7","article-title":"IGF-1R targeting in cancer \u2013 does sub-cellular localization matter?","volume":"42","author":"Soni","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0315","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-018-0806-0","article-title":"Insulin\/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer","volume":"17","author":"Mutgan","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0320","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.gendis.2022.03.002","article-title":"Drugging IGF-1R in cancer: New insights and emerging opportunities","volume":"10","author":"Wang","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.ejpb.2025.114915_b0325","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.2147\/IJN.S177993","article-title":"Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer","volume":"13","author":"Qiu","year":"2018","journal-title":"IJN"},{"key":"10.1016\/j.ejpb.2025.114915_b0330","doi-asserted-by":"crossref","first-page":"10279","DOI":"10.3390\/ijms231810279","article-title":"The Proteoglycan glypican-1 as a possible candidate for innovative targeted therapeutic strategies for pancreatic ductal adenocarcinoma","volume":"23","author":"Busato","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.ejpb.2025.114915_b0335","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1158\/1535-7163.MCT-21-0335","article-title":"Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody\u2013drug conjugates in pancreatic cancer","volume":"20","author":"Tsujii","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2025.114915_b0340","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037431","article-title":"Prognostic significance of tissue factor in patients with pancreatic cancer: a systematic review protocol","volume":"10","author":"Li","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejpb.2025.114915_b0345","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/jth.14246","article-title":"Tissue factor at the crossroad of coagulation and cell signaling","volume":"16","author":"Zelaya","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejpb.2025.114915_b0350","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0355","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol. 741"},{"key":"10.1016\/j.ejpb.2025.114915_b0360","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2011","key":"10.1016\/j.ejpb.2025.114915_b0365","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1200\/JCO.2010.34.2774","article-title":"Focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage IV Non\u2013small-cell lung cancer","volume":"29","author":"Azzoli","year":"2011","journal-title":"JCO"},{"key":"10.1016\/j.ejpb.2025.114915_b0370","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2147\/DDDT.S105442","article-title":"Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejpb.2025.114915_b0375","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic Pancreatic Cancer: ASCO Guideline Update","volume":"38","author":"Sohal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0380","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ctrv.2013.05.001","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients","volume":"39","author":"Roengvoraphoj","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejpb.2025.114915_b0385","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.10194","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?","volume":"194","author":"Normanno","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejpb.2025.114915_b0390","first-page":"3","article-title":"Research progress in tumor-related resistance mechanisms of oxaliplatin","volume":"42","author":"Ren","year":"2021","journal-title":"Shanghai Med. Pharm. J."},{"key":"10.1016\/j.ejpb.2025.114915_b0395","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.ejpb.2025.114915_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0405","doi-asserted-by":"crossref","first-page":"15110","DOI":"10.3748\/wjg.v20.i41.15110","article-title":"S-1 in the treatment of pancreatic cancer","volume":"20","author":"Sudo","year":"2014","journal-title":"WJG"},{"key":"10.1016\/j.ejpb.2025.114915_b0410","first-page":"S24","article-title":"Retrospective evaluation of drug-drug interactions with erlotinib and gefitinib use in the military health system","volume":"40","author":"Luong","year":"2023","journal-title":"Fed. Pract."},{"key":"10.1016\/j.ejpb.2025.114915_b0415","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fonc.2018.00094","article-title":"First-line treatment in EGFR mutant non-small cell lung cancer: is there a best option?","volume":"8","author":"Bulbul","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0420","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0425","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1543526","article-title":"Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5","volume":"8","author":"Tsukita","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejpb.2025.114915_b0430","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Pancreatic Adenocarcinoma. Version 2.2025., (n.d.). https:\/\/nccn.medlive.cn\/index (accessed February 21, 2025)."},{"key":"10.1016\/j.ejpb.2025.114915_b0435","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0440","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0445","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12957-021-02291-6","article-title":"The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis","volume":"19","author":"Zhang","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0450","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2468-1253(18)30196-1","article-title":"Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2025.114915_b0455","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2025.114915_b0460","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2025.114915_b0465","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2025.114915_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100238","article-title":"Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): amulticenter survey","volume":"6","author":"Orsi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejpb.2025.114915_b0475","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med. 379"},{"key":"10.1016\/j.ejpb.2025.114915_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216782","article-title":"Conquering chemoresistance in pancreatic cancer: exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia","volume":"588","author":"Chintamaneni","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b0485","doi-asserted-by":"crossref","DOI":"10.1007\/s11306-018-1452-7","article-title":"Insights into gemcitabine resistance and the potential for therapeutic monitoring","volume":"14","author":"Gebregiworgis","year":"2018","journal-title":"Metabolomics"},{"key":"10.1016\/j.ejpb.2025.114915_b0490","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7150\/ijbs.14951","article-title":"The landscape of pancreatic cancer therapeutic resistance mechanisms","volume":"12","author":"Chand","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejpb.2025.114915_b0495","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919875568","article-title":"An update on treatment options for pancreatic adenocarcinoma","volume":"11","author":"Lambert","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejpb.2025.114915_b0500","doi-asserted-by":"crossref","DOI":"10.7860\/JCDR\/2016\/19345.8776","article-title":"Current development of anti-cancer drug S-1","author":"Chhetri","year":"2016","journal-title":"JCDR"},{"key":"10.1016\/j.ejpb.2025.114915_b0505","first-page":"294","article-title":"Clinical comprehensive evaluation of albumin-bound paclitaxel in the treatment of metastatic pancreatic cancer","volume":"32","author":"Zhao","year":"2023","journal-title":"Chin. J. Pharmacoepidemiol."},{"key":"10.1016\/j.ejpb.2025.114915_b0510","first-page":"9","article-title":"Progress on targets and therapeutic drugs for pancreatic cancer","volume":"58","author":"Yang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2025.114915_b0515","first-page":"312","article-title":"A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ejpb.2025.114915_b0520","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2025.114915_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114357","article-title":"Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment","volume":"187","author":"Tarannum","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2025.114915_b0530","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/pharmaceutics15051318","article-title":"Drug delivery strategies for the treatment of pancreatic cancer","volume":"15","author":"Olajubutu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b0535","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejpb.2023.09.014","article-title":"Liposomal nanostructures for Gemcitabine and Paclitaxel delivery in pancreatic cancer","volume":"192","author":"Silli","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114915_b0540","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/pharmaceutics14030531","article-title":"Liposomes as tools to improve therapeutic enzyme performance","volume":"14","author":"Cruz","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b0545","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/21691401.2023.2247036","article-title":"Liposomes for drug delivery: review of vesicular composition, factors affecting drug release and drug loading in liposomes","volume":"51","author":"Pande","year":"2023","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0550","doi-asserted-by":"crossref","unstructured":"J.M. Joy, A. P, R.J. M, P.K. Dara, V. Renuka, R. Anandan, Liposome mediated encapsulation and role of chitosan on modulating liposomal stability to deliver potential bioactives-A review, Food Hydrocolloids for Health 4 (2023) 100142. 10.1016\/j.fhfh.2023.100142.","DOI":"10.1016\/j.fhfh.2023.100142"},{"key":"10.1016\/j.ejpb.2025.114915_b0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2022.12.013","article-title":"Liposome-based diagnostic and therapeutic applications for pancreatic cancer","volume":"157","author":"Raza","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2025.114915_b0560","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3390\/ijms24032643","article-title":"Liposomes for tumor targeted therapy: a review","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2025.114915_b0565","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17425247.2020.1723544","article-title":"Endocytosis of ATB0, (SLC6A14)-targeted liposomes for drug delivery and its therapeutic application for pancreatic cancer","volume":"17","author":"Kou","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114915_b0570","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1007\/s13346-020-00884-4","article-title":"Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Drug Deliv. and Transl. Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0575","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2025.114915_b0580","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s11095-021-03045-5","article-title":"A liposomal gemcitabine, FF-10832, improves plasma stability, tumor targeting, and antitumor efficacy of gemcitabine in pancreatic cancer xenograft models","volume":"38","author":"Matsumoto","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0585","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1021\/acsomega.9b00537","article-title":"Preparation, characterization, and in vitro\/in vivo evaluation of paclitaxel-bound albumin-encapsulated liposomes for the treatment of pancreatic cancer","volume":"4","author":"Okamoto","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2025.114915_b0590","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s42823-022-00364-4","article-title":"Carbon nanotubes in biomedical applications: current status, promises, and challenges","volume":"32","author":"Murjani","year":"2022","journal-title":"Carbon Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b0595","doi-asserted-by":"crossref","unstructured":"F.F. Contreras-Torres, D. Salas-Trevi\u00f1o, A. Soto-Dom\u00ednguez, G. De Jes\u00fas Garc\u00eda-Rivas, Carbon Nanotubes in Tumor-Targeted Chemotherapeutic Formulations: A Review of Opportunities and Challenges, ACS Appl. Nano Mater. 5 (2022) 8649\u20138679. doi: 10.1021\/acsanm.2c01118.","DOI":"10.1021\/acsanm.2c01118"},{"key":"10.1016\/j.ejpb.2025.114915_b0600","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12951-021-01174-y","article-title":"Insights on functionalized carbon nanotubes for cancer theranostics","volume":"19","author":"Tang","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118059","article-title":"Far-reaching advances in the role of carbon nanotubes in cancer therapy","author":"Faraji Dizaji","year":"2020","journal-title":"Life Sci. 257"},{"key":"10.1016\/j.ejpb.2025.114915_b0610","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/nano12132283","article-title":"Cancer targeting and diagnosis: recent trends with carbon nanotubes","volume":"12","author":"Singh","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejpb.2025.114915_b0615","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1039\/c4tb00778f","article-title":"Preparation and evaluation of polyethyleneimine-single walled carbon nanotube conjugates as vectors for pancreatic cancer treatment","volume":"2","author":"Andreoli","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejpb.2025.114915_b0620","doi-asserted-by":"crossref","first-page":"12073","DOI":"10.1038\/s41598-024-59745-6","article-title":"Multi-wall carbon Nanotube surface-based functional nanoparticles for stimuli-responsive dual pharmaceutical compound delivery","volume":"14","author":"Nabitabar","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2025.114915_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.matchemphys.2019.122435","article-title":"Systems based on carbon nanotubes with potential in cancer therapy","volume":"241","author":"Badea","year":"2020","journal-title":"Mater. Chem. Phys."},{"key":"10.1016\/j.ejpb.2025.114915_b0630","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejpb.2021.02.002","article-title":"Exosomes as new therapeutic vectors for pancreatic cancer treatment","volume":"161","author":"Oliveira","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114915_b0635","first-page":"503","article-title":"Research advances of cell drug delivery system in treatment of tumor","volume":"39","author":"Ma","year":"2024","journal-title":"Drugs Clin."},{"key":"10.1016\/j.ejpb.2025.114915_b0640","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-023-01704-0","article-title":"Clinical applications of stem cell-derived exosomes","volume":"9","author":"Tan","year":"2024","journal-title":"Sig. Transduct. Target Ther."},{"key":"10.1016\/j.ejpb.2025.114915_b0645","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.2147\/DDDT.S265423","article-title":"Exosomes-coated miR-34a Displays potent antitumor activity in pancreatic cancer both in vitro and in vivo","volume":"14","author":"Zuo","year":"2020","journal-title":"DDDT"},{"key":"10.1016\/j.ejpb.2025.114915_b0650","doi-asserted-by":"crossref","first-page":"11037","DOI":"10.1007\/s11033-022-07765-8","article-title":"Functions and clinical applications of exosomes in pancreatic cancer","volume":"49","author":"Jiang","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejpb.2025.114915_b0655","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3892\/ol.2021.12559","article-title":"Role of exosomes in pancreatic cancer (Review)","volume":"21","author":"Liu","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b0660","first-page":"380","article-title":"Research progress on exosome-based antitumor drug delivery system","volume":"37","author":"Sun","year":"2024","journal-title":"Chin J Biol."},{"key":"10.1016\/j.ejpb.2025.114915_b0665","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12935-024-03456-5","article-title":"The systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapy","volume":"24","author":"Qin","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejpb.2025.114915_b0670","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.apsb.2019.11.013","article-title":"Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer","volume":"10","author":"Zhou","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2025.114915_b0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132845","article-title":"Curcumin modulates pancreatic adenocarcinoma cell-derived exosomal function","volume":"10","author":"Osterman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2025.114915_b0680","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13346-022-01197-4","article-title":"Polymeric micelles and cancer therapy: an ingenious multimodal tumor-targeted drug delivery system","volume":"13","author":"Hari","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0685","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/pharmaceutics15112622","article-title":"Advances in polymeric micelles: responsive and targeting approaches for cancer immunotherapy in the tumor microenvironment","volume":"15","author":"Cheng","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b0690","first-page":"688","article-title":"Research progress on antitumor mechanism and nano-drug delivery system for ginsenosides","volume":"55","author":"Li","year":"2024","journal-title":"Chin. Tradit Herbal Drugs."},{"key":"10.1016\/j.ejpb.2025.114915_b0695","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.actbio.2021.04.009","article-title":"PEG-based thermosensitive and biodegradable hydrogels","volume":"128","author":"Shi","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2025.114915_b0700","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cclet.2019.02.018","article-title":"Gambogic acid-encapsulated polymeric micelles improved therapeutic effects on pancreatic cancer","volume":"30","author":"Wang","year":"2019","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b0705","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jconrel.2020.11.029","article-title":"Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer","volume":"330","author":"Lei","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2025.114915_b0710","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1039\/D3NA00397C","article-title":"Recent advances of nanocrystals in cancer theranostics","volume":"5","author":"Yenurkar","year":"2023","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.ejpb.2025.114915_b0715","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12645-022-00140-z","article-title":"Development of doped ZnO-based biomimicking and tumor-targeted nanotheranostics to improve pancreatic cancer treatment","volume":"13","author":"Barui","year":"2022","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0720","doi-asserted-by":"crossref","DOI":"10.1002\/ppsc.202200138","article-title":"Dual drug loaded nanotheranostic platforms as a novel synergistic approach to improve pancreatic cancer treatment","volume":"40","author":"Barui","year":"2023","journal-title":"Part. Part. Syst. Charact."},{"key":"10.1016\/j.ejpb.2025.114915_b0725","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915978","article-title":"Polymer nanoparticle-assisted chemotherapy of pancreatic cancer","volume":"12","author":"Su","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejpb.2025.114915_b0730","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for cancer therapy: current progress and challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b0735","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1021\/acsanm.9b00439","article-title":"Silver-nanoparticle-mediated therapies in the treatment of pancreatic cancer","volume":"2","author":"Foulkes","year":"2019","journal-title":"ACS Appl Nano Mater."},{"key":"10.1016\/j.ejpb.2025.114915_b0740","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.7150\/thno.22834","article-title":"UTMD-promoted co-delivery of gemcitabine and miR-21 inhibitor by dendrimer-entrapped gold nanoparticles for pancreatic cancer therapy","volume":"8","author":"Lin","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2025.114915_b0745","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.625084","article-title":"Dual targeting EGFR and STAT3 with erlotinib and alantolactone co-loaded PLGA nanoparticles for pancreatic cancer treatment","volume":"12","author":"Bao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114915_b0750","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1166\/jnn.2020.18608","article-title":"Therapeutic effects of paclitaxel loaded polyethylene glycol-polylactic acid-glycolic acid copolymer nanoparticles on pancreatic cancer in rats","volume":"20","author":"Fu","year":"2020","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0755","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/17425247.2016.1178234","article-title":"Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells","volume":"13","author":"Coelho","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114915_b0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.ejpb.2025.114915_b0765","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.actbio.2019.10.022","article-title":"Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer","volume":"101","author":"Li","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2025.114915_b0770","doi-asserted-by":"crossref","first-page":"28160","DOI":"10.1021\/acsanm.4c04733","article-title":"Nanosized liposomes loaded with paclitaxel palmitate and gemcitabine hydrochloride for anti-pancreatic cancer therapy","volume":"7","author":"Li","year":"2024","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.ejpb.2025.114915_b0775","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.actbio.2022.09.065","article-title":"Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery","volume":"154","author":"Patel","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2025.114915_b0780","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.3390\/pharmaceutics15102421","article-title":"Hydrogel-based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment","volume":"15","author":"Liu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120139","article-title":"Thermosensitive and Biodegradable Hydrogel Encapsulating Targeted Nanoparticles for the Sustained Co-delivery of Gemcitabine and Paclitaxel to Pancreatic Cancer Cells","volume":"593","author":"Shabana","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114915_b0790","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1021\/acs.nanolett.2c01994","article-title":"Injectable immunotherapeutic hydrogel containing RNA-loaded lipid nanoparticles reshapes tumor microenvironment for pancreatic cancer therapy","volume":"22","author":"Gao","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b0795","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/adma.200501612","article-title":"Hydrogels in biology and medicine: from molecular principles to bionanotechnology","volume":"18","author":"Peppas","year":"2006","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejpb.2025.114915_b0800","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1038\/s41467-019-13115-3","article-title":"Extravascular gelation shrinkage-derived internal stress enables tumor starvation therapy with suppressed metastasis and recurrence","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2025.114915_b0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodhyd.2022.108013","article-title":"Targeted delivery of hydrogels in human gastrointestinal tract: a review","volume":"134","author":"Yang","year":"2023","journal-title":"Food Hydrocoll."},{"key":"10.1016\/j.ejpb.2025.114915_b0810","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/pharmaceutics12121188","article-title":"Hydrogels as drug delivery systems: a review of current characterization and evaluation techniques","volume":"12","author":"Vigata","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b0815","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0820","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1208\/aapsj0902015","article-title":"Targeted pharmaceutical nanocarriers for cancer therapy and imaging","volume":"9","author":"Torchilin","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2025.114915_b0825","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2025.114915_b0830","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3390\/biomedicines9111694","article-title":"Hydrogels: 3D drug delivery systems for nanoparticles and extracellular vesicles","volume":"9","author":"Chabria","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejpb.2025.114915_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.indcrop.2023.116654","article-title":"pH-responsive polyacrylic acid (PAA)-carboxymethyl cellulose (CMC) hydrogel incorporating halloysite nanotubes (HNT) for controlled curcumin delivery","volume":"197","author":"Pourmadadi","year":"2023","journal-title":"Ind. Crop. Prod."},{"key":"10.1016\/j.ejpb.2025.114915_b0840","doi-asserted-by":"crossref","first-page":"31402","DOI":"10.1039\/D2RA05639A","article-title":"In-depth drug delivery to tumoral soft tissues via pH responsive hydrogel","volume":"12","author":"Sarwar","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2025.114915_b0845","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/pharmaceutics14102028","article-title":"Progress of research in in situ smart hydrogels for local antitumor therapy: a review","volume":"14","author":"Zhao","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b0850","article-title":"Hydrogels for tissue engineering: addressing key design needs toward clinical translation","volume":"10","author":"Xu","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0855","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-022-01320-5","article-title":"Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies","volume":"15","author":"Tian","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103459","article-title":"Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: an update","volume":"73","author":"Mohammadzadeh","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejpb.2025.114915_b0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112944","article-title":"Effect of surface ligand modification on the properties of anti-tumor nanocarrier","volume":"220","author":"Ying","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2025.114915_b0870","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117550","article-title":"Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer","volume":"180","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2025.114915_b0880","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12951-023-02183-9","article-title":"TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer","volume":"21","author":"Xu","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0885","doi-asserted-by":"crossref","first-page":"14700","DOI":"10.1021\/acs.jmedchem.3c01210","article-title":"hIMB1636-MMAE, a Novel TROP2-targeting antibody-drug conjugate exerting potent antitumor efficacy in pancreatic cancer","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114915_b0890","doi-asserted-by":"crossref","unstructured":"L.E. Lamberts, C.W. Menke-van Der Houven Van Oordt, E.J. Ter Weele, F. Bensch, M.M. Smeenk, J. Voortman, O.S. Hoekstra, S.P. Williams, B.M. Fine, D. Maslyar, J.R. De Jong, J.A. Gietema, C.P. Schr\u00f6der, A.H.H. Bongaerts, M.N. Lub-de Hooge, H.M.W. Verheul, S.M. Sanabria Bohorquez, A.W.J.M. Glaudemans, E.G.E. De Vries, ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody\u2013drug conjugate treatment, Clin. Cancer Res. 22 (2016) 1642\u20131652. doi: 10.1158\/1078-0432.CCR-15-1272.","DOI":"10.1158\/1078-0432.CCR-15-1272"},{"key":"10.1016\/j.ejpb.2025.114915_b0895","doi-asserted-by":"crossref","unstructured":"S. Golfier, C. Kopitz, A. Kahnert, I. Heisler, C.A. Schatz, B. Stelte-Ludwig, A. Mayer-Bartschmid, K. Unterschemmann, S. Bruder, L. Linden, A. Harrenga, P. Hauff, F.-D. Scholle, B. M\u00fcller-Tiemann, B. Kreft, K. Ziegelbauer, Anetumab ravtansine: a novel mesothelin-targeting antibody\u2013drug conjugate cures tumors with heterogeneous target expression favored by bystander effect, molecular cancer therapeutics 13 (2014) 1537\u20131548. doi: 10.1158\/1535-7163.MCT-13-0926.","DOI":"10.1158\/1535-7163.MCT-13-0926"},{"key":"10.1016\/j.ejpb.2025.114915_b0900","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.2147\/IJN.S34801","article-title":"A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer","author":"Chen","year":"2012","journal-title":"IJN"},{"key":"10.1016\/j.ejpb.2025.114915_b0905","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2022.08.010","article-title":"Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer","volume":"253","author":"Bose","year":"2023","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0910","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12885-018-4393-7","article-title":"Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles","volume":"18","author":"Wu","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b0915","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","article-title":"Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody\u2013drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer","volume":"27","author":"Liu","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b0920","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.7150\/thno.15164","article-title":"Ultrasound-mediated microbubble destruction (UMMD) facilitates the delivery of CA19-9 targeted and paclitaxel loaded mPEG-PLGA-PLL nanoparticles in pancreatic cancer","volume":"6","author":"Xing","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2025.114915_b0925","doi-asserted-by":"crossref","unstructured":"S. Gupta, J.D. McDonald, R.I. Ayabe, T.M. Khan, L.A. Gamble, A.J. Rossi, S. Sinha, C. Hannah, D. Mabry-Hrones, M.C.M. B, A.M. Blakely, T.F. Greten, J.L. Davis, J.M. Hernandez, Perioperative MVT-5873, a fully human monoclonal antibody against a CA 19-9 epitope, for operable CA 19-9 producing pancreatic cancers, cholangiocarcinomas, and metastatic colorectal cancers, J. Clin. Oncol. 38 (2020) TPS4655\u2013TPS4655. doi: 10.1200\/jco.2020.38.15_suppl.tps4655.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4655"},{"key":"10.1016\/j.ejpb.2025.114915_b0930","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/pharmaceutics16020248","article-title":"Different targeting ligands-mediated drug delivery systems for tumor therapy","volume":"16","author":"Yan","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b0935","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1111\/cas.16335","article-title":"Anti\u2010tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models","volume":"115","author":"Tsumura","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejpb.2025.114915_b0940","article-title":"Humanized dual-targeting antibody\u2013drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity","author":"Wang","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejpb.2025.114915_b0945","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12274-023-6245-2","article-title":"EGFR-targeted and gemcitabine-incorporated chemogene for combinatorial pancreatic cancer treatment","volume":"17","author":"Xie","year":"2024","journal-title":"Nano Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121134","article-title":"Active targeting strategy in nanomedicines using anti-EGFR ligands \u2013 a promising approach for cancer therapy and diagnosis","volume":"609","author":"Nguyen","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114915_b0955","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/nn800551s","article-title":"Targeted killing of cancer cells in vivo and in vitro with egf-directed carbon nanotube-based drug delivery","volume":"3","author":"Bhirde","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2025.114915_b0960","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/jat.1742","article-title":"Raman spectroscopy as a detection and analysis tool for in vitro specific targeting of pancreatic cancer cells by EGF\u2010conjugated, single\u2010walled carbon nanotubes","volume":"32","author":"Karmakar","year":"2012","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejpb.2025.114915_b0965","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1021\/acs.biomac.5b01419","article-title":"EGFR-targeted polymeric mixed micelles carrying gemcitabine for treating pancreatic cancer","volume":"17","author":"Mondal","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2025.114915_b0970","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/08820139.2019.1688828","article-title":"Nanobodies in human infections: prevention, detection, and treatment","volume":"49","author":"Sanaei","year":"2020","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.ejpb.2025.114915_b0975","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","article-title":"Increased tumor penetration of single-domain antibody\u2013drug conjugates improves in vivo efficacy in prostate cancer models","volume":"80","author":"Nessler","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0980","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b0985","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.3390\/pharmaceutics14122574","article-title":"Investigation of trends in the research on transferrin receptor-mediated drug delivery via a bibliometric and thematic analysis","volume":"14","author":"Kaur","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b0990","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/jbm.a.35286","article-title":"Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells: TARGETED DELIVERY OF BORTEZOMIB TO PANCREATIC CANCER CELLS","volume":"103","author":"Frasco","year":"2015","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.ejpb.2025.114915_b0995","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2016.03.023","article-title":"Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression","volume":"232","author":"Lei","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2025.114915_b1000","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12951-024-02665-4","article-title":"Targeted delivery of CEBPA-saRNA for the treatment of pancreatic ductal adenocarcinoma by transferrin receptor aptamer decorated tetrahedral framework nucleic acid","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2025.114915_b1005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/cgt.2013.9","article-title":"Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy","volume":"20","author":"Camp","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejpb.2025.114915_b1010","doi-asserted-by":"crossref","first-page":"10760","DOI":"10.1021\/jacs.9b03720","article-title":"Elucidation and Structural Modeling of CD71 as a Molecular Target for Cell-specific Aptamer Binding","volume":"141","author":"Wu","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2025.114915_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173814","article-title":"Enhanced targeting of 3D pancreatic cancer spheroids by aptamer-conjugated polymeric micelles with deep tumor penetration","volume":"894","author":"Tian","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114915_b1020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2021.03.010","article-title":"Exosomal integrins and their influence on pancreatic cancer progression and metastasis","volume":"507","author":"Casari","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2025.114915_b1025","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41598-019-39628-x","article-title":"Blockade of integrin \u03b13 attenuates human pancreatic cancer via inhibition of EGFR signalling","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2025.114915_b1030","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.1021\/acsami.0c01069","article-title":"\u03b13\u03b21 integrin-targeting polymersomal docetaxel as an advanced nanotherapeutic for nonsmall cell lung cancer treatment","volume":"12","author":"Zou","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2025.114915_b1035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-01872-7","article-title":"Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer","volume":"9","author":"Zhou","year":"2024","journal-title":"Sig. Transduct Target Ther."},{"key":"10.1016\/j.ejpb.2025.114915_b1040","article-title":"Integrin\u2010Enriched membrane nanocarrier for the specific delivery of RGD\u2010modified relaxin analog to inhibit pancreatic cancer liver metastasis through reversing hepatic stellate cell activation","volume":"32","author":"Zhang","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejpb.2025.114915_b1045","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.86971","article-title":"Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion","volume":"12","author":"Tomas Bort","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.ejpb.2025.114915_b1050","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1021\/acs.molpharmaceut.7b00583","article-title":"Development of a ligand-targeted therapeutic agent for neurokinin-1 receptor expressing cancers","volume":"14","author":"Kanduluru","year":"2017","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b1055","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2012.00184","article-title":"Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy","volume":"3","author":"Wu","year":"2013","journal-title":"Front. Endocrin."},{"key":"10.1016\/j.ejpb.2025.114915_b1060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40495-015-0044-8","article-title":"Potential of CXCR4\/CXCL12 chemokine axis in cancer drug delivery","volume":"2","author":"Wang","year":"2016","journal-title":"Curr Pharmacol. Rep."},{"key":"10.1016\/j.ejpb.2025.114915_b1065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40164-016-0050-5","article-title":"Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice","volume":"5","author":"Liu","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105010","article-title":"CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent","volume":"159","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2025.114915_b1075","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1021\/acsnano.5b01288","article-title":"IGF1 receptor targeted theranostic nanoparticles for targeted and image-guided therapy of pancreatic cancer","volume":"9","author":"Zhou","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2025.114915_b1080","doi-asserted-by":"crossref","unstructured":"H. Zhou, W. Qian, F.M. Uckun, Z. Zhou, L. Wang, A. Wang, H. Mao, L. Yang, IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer, in: T. George, A.K. Dutta, M.S. Islam (Eds.), Baltimore, Maryland, United States, 2016: p. 98361O. doi: 10.1117\/12.2224914.","DOI":"10.1117\/12.2224914"},{"key":"10.1016\/j.ejpb.2025.114915_b1085","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/molecules29030675","article-title":"Co-delivery of gemcitabine and honokiol by lipid bilayer-coated mesoporous silica nanoparticles enhances pancreatic cancer therapy via targeting depletion of tumor stroma","volume":"29","author":"Liu","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2025.114915_b1090","doi-asserted-by":"crossref","first-page":"iv6","DOI":"10.1016\/S0923-7534(19)66469-0","article-title":"O-0004 updated analysis of phase II study of the anti-IGF-1R antibody MK-0646 with gemcitabine +\/- erlotinib for advanced pancreatic cancer (APC)","volume":"23","author":"Shroff","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b1095","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.neo.2021.07.006","article-title":"A glypican-1-targeted antibody-drug conjugate exhibits potent tumorgrowth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma","volume":"23","author":"Munekage","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejpb.2025.114915_b1100","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1039\/D1MA00225B","article-title":"Anti-GPC1-modified mesoporous silica nanoparticles as nanocarriers for combination therapy and targeting of PANC-1 cells","volume":"2","author":"Estev\u00e3o","year":"2021","journal-title":"Mater. Adv."},{"key":"10.1016\/j.ejpb.2025.114915_b1105","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","article-title":"Anti-glypican-1 antibody\u2013drug conjugate is a potential therapy against pancreatic cancer","volume":"122","author":"Nishigaki","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b1110","doi-asserted-by":"crossref","unstructured":"Y. Mu, D. Wang, L. Bie, S. Luo, X. Mu, Y. Zhao, Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer, Aging 12 (2020) 19585\u201319596. doi: 10.18632\/aging.103918.","DOI":"10.18632\/aging.103918"},{"key":"10.1016\/j.ejpb.2025.114915_b1115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.biomaterials.2014.10.069","article-title":"Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer","volume":"39","author":"Ahn","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2025.114915_b1120","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1021\/acs.molpharmaceut.0c00127","article-title":"86\/90 Y-labeled monoclonal antibody targeting tissue factor for pancreatic cancer theranostics","volume":"17","author":"Ferreira","year":"2020","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114915_b1125","article-title":"A Novel c-MET-targeting antibody-drug conjugate for pancreatic cancer","volume":"11","author":"Jin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b1130","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1158\/1078-0432.CCR-20-3210","article-title":"A MET targeting antibody\u2013drug conjugate overcomes gemcitabine resistance in pancreatic cancer","volume":"27","author":"Cazes","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114915_b1135","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jconrel.2022.05.012","article-title":"Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer","author":"Al Faruque","year":"2022","journal-title":"J. Control. Release 347"},{"key":"10.1016\/j.ejpb.2025.114915_b1140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejpb.2021.05.014","article-title":"Phenylboronic acid modified nanoparticles simultaneously target pancreatic cancer and its metastasis and alleviate immunosuppression","volume":"165","author":"Lu","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114915_b1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.flatc.2025.100834","article-title":"Synergistic combinational photothermal therapy-based approaches for cancer treatment","volume":"50","author":"Naik","year":"2025","journal-title":"FlatChem"},{"key":"10.1016\/j.ejpb.2025.114915_b1150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2020.06.032","article-title":"Photothermal therapy","volume":"325","author":"Zhi","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2025.114915_b1155","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201700448","article-title":"A comparative study of clinical intervention and interventional photothermal therapy for pancreatic cancer","volume":"29","author":"Hu","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejpb.2025.114915_b1160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.colsurfb.2017.09.010","article-title":"PEGylated thermosensitive lipid-coated hollow gold nanoshells for effective combinational chemo-photothermal therapy of pancreatic cancer","volume":"160","author":"Poudel","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2025.114915_b1165","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1039\/C8BM00454D","article-title":"Black TiO2-based nanoprobes for T1-weighted MRI-guided photothermal therapy in CD133 high expressed pancreatic cancer stem-like cells\u2020","volume":"6","author":"Wang","year":"2018","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejpb.2025.114915_b1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2019.122949","article-title":"Silica\/gold nanoplatform combined with a thermosensitive gel for imaging-guided interventional therapy in PDX of pancreatic cancer","volume":"382","author":"Xing","year":"2020","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejpb.2025.114915_b1175","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.7150\/thno.17841","article-title":"SiRNA delivery with PEGylated graphene oxide nanosheets for combined photothermal and genetherapy for pancreatic cancer","volume":"7","author":"Yin","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2025.114915_b1180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cancers10040103","article-title":"Role of gene therapy in pancreatic cancer\u2014a review","volume":"10","author":"Sato-Dahlman","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2025.114915_b1185","article-title":"Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer","volume":"e202000875","author":"McAndrews","year":"2021","journal-title":"Life Sci. Alliance 4"},{"key":"10.1016\/j.ejpb.2025.114915_b1190","unstructured":"J. Min, S. Peng, N. DU, R. An, X. Zhen, J. Cao, C. Zhou, Z. Li, Enhanced tumoricidal activity of PD-1 antibody-secreting c-Met CAR-T cells against pancreatic cancer cells, Nan Fang Yi Ke Da Xue Xue Bao 44 (2024) 1976\u20131984. doi: 10.12122\/j.issn.1673-4254.2024.10.16."},{"key":"10.1016\/j.ejpb.2025.114915_b1195","first-page":"A151","article-title":"143\u2005Mesothelin (MSLN) targeting allogeneic CAR T cells engineered to overcome tumor immunosuppressive microenvironment","volume":"9","author":"Schiffer-Mannioui","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejpb.2025.114915_b1200","doi-asserted-by":"crossref","first-page":"8586","DOI":"10.1039\/D3TB01358H","article-title":"Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies","volume":"11","author":"Guo","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejpb.2025.114915_b1205","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrclinonc.2018.27","article-title":"Immunotherapy: Cancer immunotherapy and the value of cure","volume":"15","author":"Paggio","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b1210","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.omto.2022.01.010","article-title":"The next wave of cellular immunotherapies in pancreatic cancer","volume":"24","author":"Yeo","year":"2022","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.ejpb.2025.114915_b1215","first-page":"111","article-title":"Immunotherapy for pancreatic cancer and its latest progress","volume":"31","author":"Wang","year":"2022","journal-title":"Chin. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2025.114915_b1220","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13543784.2022.2037552","article-title":"Novel systemic treatment approaches for metastatic pancreatic cancer","volume":"31","author":"Dorman","year":"2022","journal-title":"Expert Opin. Invest. Drugs"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125002929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125002929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:53:22Z","timestamp":1764953602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125002929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":244,"alternative-id":["S0939641125002929"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114915","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of design strategies for active targeted drug delivery systems for pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114915"}}